1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

CombiGene: New priorities after strategic decision

  • Terminating the CG01 programme
  • Implementing cost savings to prolong the financial runway
  • Our fair value estimate is under review

Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway. Peter Ekolind, the CEO, will comment in a live webcast hosted by Västra Hamnen Corporate Finance on Thursday October 31 at 3pm. After evaluating the prospects of the CG01 programme, including generated preclinical data, IP situation, capital requirements and likelihood of success, CombiGene decided to terminate the programme. The company will still be looking for a potential partner for CG01. CombiGene will now focus its R&D investments on the COZY programme for the treatment of chronic pain. Our fair value estimate is under review.

The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2024-10-29, kl 16:15
Källa MFN
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.